HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Andrew H. Foster David J. Underhill Richard E. Clark Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foster, A. H. Articles by Clark, R. E. Search for Related Content PubMed PubMed Citation Articles by Foster, A. H. Articles by Clark, R. E.

Ann Thorac Surg 1987;44:568-577
© 1987 The Society of Thoracic Surgeons

---

Articles

Intrinsic Failure of Hancock Mitral Bioprostheses: 10- to 15-Year Experience

From the Surgery Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

^* Address reprint requests to Dr. Clark, National Heart, Lung, and Blood Institute, National Institutes of Health, Bldg 10, Room 2N244, 9000 Rockville Pike, Bethesda, MD 20892

Hancock porcine bioprostheses have been implanted in the mitral position at the National Institutes of Health since July, 1970. Eight models (330, 330A, 330B, 330C, 332, 340, 341, and 342) were used during a 54-month period ending December, 1974, and 100 consecutive surviving patients were evaluated for subsequent bioprosthetic valve failure and prosthesis-related complications by annual clinic examinations and serial hemodynamic studies. Actuarial patient survival was 76 ± 4%, 51 ± 5%, and 30 ± 6% after 5, 10, and 15 years, respectively. Intrinsic valve failure, defined as structural degeneration of bioprosthetic tissue or stent geometry alteration or both, in the absence of prior infection, occurred in 23 patients. The linear occurrence rate of bioprosthetic valve failure was 0.2%, 5%, and 15% per patient-year, and it affected 1 patient, 14 patients, and 8 patients at sequential 5-year milestones. The actuarial freedom from valve failure was 99 ± 1%, 75 ± 6%, 58 ± 8%, and 40 ± 12% after 5, 10, 12, and 14 years, respectively. The valve durability of early Hancock bioprostheses (models 330 through 341; N = 39) was not appreciably different from that of the current model 342 valves (N = 61). However, an increased incidence of intrinsic valve failure was observed for the first polypropylene-stented valve type (model 330) compared with the currently available model 342 valve (8/16, 50%, versus 12/61, 20%; p = 0.034). The yearly occurrence rate of prosthesis-related complications remained constant, but the rate of intrinsic valve failure increased in a progressive, nonlinear fashion. The high intrinsic failure rate of the Hancock porcine bioprosthesis after 10 to 12 years has moderated our initial enthusiasm for this valve in the mitral position, and has resulted in more frequent implantations of mechanical valve substitutes at this institution.

This article has been cited by other articles:

				H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, and H C Miller Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses Heart, July 1, 2003; 89(7): 715 - 721. [Abstract] [Full Text] [PDF]

				A. S. Geha, M. G. Massad, and N. J. Snow Replacement of degenerated mitral and aortic bioprostheses without explantation Ann. Thorac. Surg., November 1, 2001; 72(5): 1509 - 1514. [Abstract] [Full Text] [PDF]

				M. Dahm, M. Husmann, E. Mayer, D. Prufer, E. Groh, and H. Oelert Relevance of immunologic reactions for tissue failure of bioprosthetic heart valves Ann. Thorac. Surg., August 1, 1995; 60(suppl_2): S348 - S352. [Abstract] [PDF]

				S. Westaby, N. Amarasena, O. Ormerod, G. A. Chandima Amarasena, and R. Pillai Aortic valve replacement with the freestyle stentless xenograft Ann. Thorac. Surg., August 1, 1995; 60(suppl_2): S422 - S427. [Abstract] [PDF]

				S. Silberman and B. S. Goldman Premature leaflet dysfunction in a tricuspid bioprosthesis J. Thorac. Cardiovasc. Surg., June 1, 1994; 107(6): 1542 - 1543. [Full Text]

				J. P. Gott, Pan-Chih, L. M. A. Dorsey, J. L. Jay, G. K. Jett, F. J. Schoen, J.-M. Girardot, and R. A. Guyton Calcification of porcine valves: A successful new method of antimineralization Ann. Thorac. Surg., February 1, 1992; 53(2): 207 - 216. [Abstract] [PDF]

				A. Starr and G. L. Grunkemeier The Expected Lifetime of Porcine Valves Ann. Thorac. Surg., September 1, 1989; 48(3): 317 - 318. [PDF]

				D. J. Magilligan Jr, J. W. Lewis Jr, P. Stein, and M. Alam The Porcine Bioprosthetic Heart Valve: Experience at 15 Years Ann. Thorac. Surg., September 1, 1989; 48(3): 324 - 330. [Abstract] [PDF]